AbbVie Inc. is a major American biopharmaceutical company that was founded in 2013 as a spin-off from Abbott Laboratories. Its headquarters is located in North Chicago, Illinois. AbbVie operates in over 175 countries and employs more than 50,000 people worldwide.
📊 Financial Highlights (2024–2025)
-
Revenue (2024): $56.3 billion
-
Q1 2025 Revenue: $13.34 billion (up 8% YoY)
-
Projected EPS for 2025: $12.12–$12.32
-
Current stock price (May 2025): ~$214
-
Dividend yield: 3.7%
💊 Key Products
-
Skyrizi (risankizumab): for psoriasis and inflammatory bowel diseases
-
Rinvoq (upadacitinib): for rheumatoid arthritis, eczema, and other autoimmune diseases
-
Humira (adalimumab): once the best-selling drug, but sales declined 49% in 2024 due to biosimilar competition
Skyrizi and Rinvoq are projected to generate over $31 billion in annual sales by 2027, helping to offset Humira’s decline.
🧬 Research, Acquisitions & Pipeline
-
Oncology: developing new drugs, including Teliso-V for non-small cell lung cancer
-
Neurology: acquired Cerevel Therapeutics for $8.7 billion to strengthen its neuroscience portfolio
-
Partnerships: signed a $65 million collaboration with EvolveImmune Therapeutics to develop multi-specific cancer drugs
📈 Analyst Outlook
AbbVie is rated as a “Buy” by multiple analysts:
-
TD Cowen: price target $225
-
Piper Sandler: price target $220
-
Guggenheim: price target $212
⚠️ Risks
-
Humira revenue decline due to patent expiration and generic competition
-
Regulatory risks including possible U.S. trade tariffs impacting production and costs
AbbVie is a leading player in the pharmaceutical industry, known for its strong product pipeline, innovation, and strategic growth. It remains attractive to investors thanks to consistent earnings, expanding drug approvals, and a focus on high-growth therapeutic areas.